Gianluca T.
- Country
- Italy
- Department
- UOC Oncologia
Research Overview
- Switch Maintenance with Paclitaxel, Ramucirumab and Tislelizumab vs Continued Chemotherapy plus Tislelizumab in HER2‑negative, PD‑L1‑positive Gastroesophageal Adenocarcinoma
- Evaluation of ctDNA Clearance in Stage III and High-Risk Stage II Resected Colon Cancer Using FOLFOXIRI, Trifluridine/Tipiracil, and Drug Combinations
- Evaluation of ABP 206 Versus Nivolumab in Treatment-Naïve Patients with Unresectable or Metastatic Melanoma
Data & Insights
Has run more than one trial at 47 of 215 partner sites.
Specializations
Gastrointestinal Oncology
The investigator specializes in treating advanced forms of gastrointestinal cancers, with particular emphasis on colon cancer and pancreatic cancer management.
- Stage III and high-risk stage II colon cancer treatment
- Advanced pancreatic cancer therapeutics
- Post-operative cancer care
Their work encompasses comprehensive treatment approaches in gastrointestinal oncology.
Precision Medicine
The investigator focuses on innovative diagnostic approaches, particularly utilizing circulating tumor DNA testing for treatment monitoring and personalized therapy selection.
- Molecular-guided treatment strategies
- HER2-positive colon cancer therapy
- Post-surgical treatment optimization
Their approach integrates molecular diagnostics with targeted therapeutic interventions.
Treatment Innovation
The investigator explores novel therapeutic combinations including maintenance therapy strategies and intensive post-operative treatments.
- Combination chemotherapy protocols
- Switch maintenance strategies
- Adjuvant therapy optimization
Their work involves evaluating various treatment sequences and combinations.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.